Zacks Investment Research downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a research report released on Tuesday.

According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “

Several other equities analysts also recently commented on OSUR. Canaccord Genuity reissued a buy rating and issued a $24.00 price objective on shares of OraSure Technologies in a research note on Friday, February 2nd. BidaskClub raised shares of OraSure Technologies from a buy rating to a strong-buy rating in a research note on Saturday, January 20th. ValuEngine downgraded shares of OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Finally, Jefferies Group downgraded shares of OraSure Technologies from a buy rating to a hold rating in a research note on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. OraSure Technologies currently has an average rating of Buy and a consensus price target of $22.25.

OraSure Technologies (NASDAQ OSUR) opened at $17.28 on Tuesday. The company has a market cap of $1,091.67, a P/E ratio of 33.88, a P/E/G ratio of 4.60 and a beta of 1.43. OraSure Technologies has a 52 week low of $10.28 and a 52 week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The business had revenue of $52.00 million during the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The firm’s revenue was up 46.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.13 EPS. equities analysts anticipate that OraSure Technologies will post 0.31 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in OSUR. Oppenheimer Asset Management Inc. bought a new position in shares of OraSure Technologies during the third quarter valued at $186,000. Shikiar Asset Management Inc. bought a new position in shares of OraSure Technologies during the fourth quarter valued at $207,000. Piedmont Investment Advisors LLC bought a new position in shares of OraSure Technologies during the second quarter valued at $216,000. Koch Industries Inc. bought a new position in shares of OraSure Technologies during the second quarter valued at $216,000. Finally, ARP Americas LLC bought a new position in shares of OraSure Technologies during the third quarter valued at $221,000. 91.62% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Lowers OraSure Technologies (OSUR) to Hold” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2018/02/14/zacks-investment-research-lowers-orasure-technologies-osur-to-hold.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.